A double-blind, randomized, placebo-controlled trial of ginkgo biloba extract (Egb-761) as an
add-on therapy to risperidone compared to risperidone plus placebo in the treatment of 200
treatment-naive first-episode patients with schizophrenia. The study addresses an immune
dysfunction hypothesis of schizophrenia.